Aviragen Therapeutics Inc., of Atlanta, signed a definitive agreement to receive a cash payment of $20 million from Healthcare Royalty Partners in exchange for an undisclosed portion of the company's royalty rights related to Inavir (laninamivir octanoate), an inhaled neuraminidase inhibitor that is approved in Japan for the treatment and prevention of influenza.